This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biopharmaceuticals - A Global Market Overview

DUBLIN, Ireland, November 6, 2013 /PRNewswire/ --

Research and Markets ( http://www.researchandmarkets.com/research/mdkxf2/biopharmaceuticals) has announced the addition of the "Biopharmaceuticals - A Global Market Overview" report to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Biopharmaceuticals market, estimated at US$199.7 billion globally in 2013, is further projected to reach US$497.9 billion by 2020, growing at 13.5% CAGR between 2010 and 2020. Among different product segments, monoclonal antibodies (moAb) constitutes the largest product segment in the global biopharmaceuticals market accounting for an estimated share of 25.6% in 2013, equating to US$51.1 billion. In terms of therapeutic area, neurology applications is the largest market for global biopharmaceuticals with an estimated 2013 share of 28.2% valued at US$56.3 billion, and further expected reach a projected US$144.5 billion by 2020. The report reviews, analyses and projects the biopharmaceuticals market (2010-2020) for global and the regional markets. Biopharmaceuticals product segments analyzed in this study comprises Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and others. Therapeutic areas analyzed include Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and others. 

The study includes 249 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the global market by geographic region, product segment and therapeutic area. This study profiles 25 key global players and 70 major players across North America - 24; Europe - 17; Asia-Pacific - 27 and Rest of World - 2. The report also provides the listing of the companies engaged in research and development, manufacturing and supply of biopharmaceuticals. The global list of companies covers addresses, contact numbers and the website addresses of 492 companies.

Key Topics At A Glance

Part A: Global Market Perspective 1. Introduction 2. Key Facts And Figures Of Biopharma Industry And Latest Approvals 3. Key Market Trends 4. Key Global Players 5. Key Business Trends 6. Global Market Overview Part B: Regional Market Perspective Regional Market Overview 1. North America 2. Europe 3. Asia-Pacific 4. South America 5. Rest Of World Part C: Guide To The Industry 1. North America Part D: Annexure 1. Research Methodology 2. The Questionnaire 3. Feedback

Examples of Companies Mentioned - Abbott Laboratories - Amgen - Astrazeneca - BASF - Bayer - Biocon - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Eli Lilly and Company - Genentech - Glaxosmithkline - Hospira - Johnson & Johnson - LG Life Sciences - Novartis - Novo Nordisk - Pfizer - Ranbaxy Laboratories - Roche Holding - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - UCB For more information visit http://www.researchandmarkets.com/research/mdkxf2/biopharmaceuticals

About Research and Markets

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs